One might think that we had enough crises already without creating a new one, but apparently that’s not the case. To much fanfare, the Biden Administration unveiled its long awaited “guidelines” for agency use of the march in rights provision of the Bayh-Dole Act. Ironically, it started this exercise just as it had joined every other administration in dismissing attempts to misuse the statute as a pretext for the government to micro-manage the price of a successfully commercialized government funded invention.
Recent Posts
- Federal Circuit Splits on Whether Toddler Tub May Infringe
- CAFC Rules Patent Applications are Considered Pre-AIA Prior Art By Filing Date, Not Publication Date
- The Biden Administration Rolls the Dice on NIH Patent Licensing
- The PTAB’s 70% All-Claims Invalidation Rate Continues to Be a Source of Concern
- Novartis’ Entresto Patent Claims Revived by CAFC